EW Edwards Lifesciences Corp
Orthopedic, Prosthetic & Surgical Appliances & Supplies · NYSE · SEC CIK 1099800 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY13.4%
TTM net income YoY-25.3%
TTM EPS YoY-23.7%
Revenue 3-yr CAGR9.4%
Net income 3-yr CAGR-10.6%
Margins
Gross margin78.0%
Operating margin21.6%
Net margin15.3%
FCF margin21.3%
EBITDA margin24.2%
Returns
ROE9.7%
ROA7.5%
ROIC (approx.)12.1%
Asset turnover0.49x
Leverage & solvency
Liabilities / assets22.5%
Debt / equity0.06x
Current ratio4.60x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.68x
Accruals ratio-5.1%
Payout ratio—
Capex / revenue4.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $6.07B | $5.44B |
| Cost of revenue | $1.33B | $1.12B |
| Gross profit | $4.73B | $4.32B |
| R&D expense | $1.08B | $1.05B |
| SG&A expense | $2.09B | $1.79B |
| Operating income | $1.26B | $1.38B |
| Interest expense | $20.40M | $19.80M |
| Pretax income | $1.27B | $1.55B |
| Income tax | $216.90M | $152.10M |
| Net income | $1.07B | $4.17B |
| EBITDA | $1.42B | $1.53B |
| EPS (basic) | 1.84 | 6.98 |
| EPS (diluted) | 1.83 | 6.97 |
| Weighted avg. shares (diluted) | 585.80M | 599.30M |
| Banking | ||
| Net interest income | -$20.40M | -$19.80M |
| Balance sheet | ||
| Cash & equivalents | $2.94B | $3.06B |
| Short-term investments | $1.29B | $930.70M |
| Receivables | $659.60M | $609.10M |
| Inventory | $1.13B | $1.09B |
| Current assets | $6.74B | $6.29B |
| PP&E, net | $1.81B | $1.69B |
| Goodwill | $1.77B | $1.78B |
| Intangibles | $1.13B | $1.18B |
| Total assets | $13.70B | $13.06B |
| Current liabilities | $1.81B | $1.51B |
| Long-term debt | $598.30M | $597.70M |
| Total debt | $598.30M | $597.70M |
| Total liabilities | $3.36B | $2.99B |
| Shareholders' equity | $10.34B | $10.00B |
| Net debt | -$2.34B | -$2.46B |
| Shares outstanding | 580.70M | 588.60M |
| Cash flow statement | ||
| Operating cash flow | $1.60B | $542.30M |
| Capital expenditure | $260.20M | $252.40M |
| Free cash flow | $1.33B | $289.90M |
| Investing cash flow | -$712.90M | $2.31B |
| Financing cash flow | -$956.80M | -$983.00M |
| Depreciation & amortization | $156.60M | $155.20M |
| Stock-based compensation | $158.10M | $162.30M |
| Share buybacks | $893.40M | $1.16B |
Free plan shows the latest 2 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.